Stifel Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $230
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Annabel Samimy maintains a Buy rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) and raises the price target from $225 to $230.
March 15, 2024 | 1:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Annabel Samimy maintains a Buy rating on Jazz Pharmaceuticals and raises the price target from $225 to $230.
The increase in price target by Stifel indicates a positive outlook on Jazz Pharmaceuticals' stock, suggesting potential upside. This could lead to increased investor confidence and a possible short-term price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100